These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9220293

  • 1. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A, Hudes GR, Greene F, LaCreta FP, Brennan J, O'Dwyer PJ.
    Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
    Hageboutros A, Hudes GR, Brennan J, Green F, Hoffman J, LaCreta FP, Colofiore J, Martin DS, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A, Rogatko A, Newman EM, McAleer C, Brennan J, LaCreta FP, Hudes GR, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1995 Sep 04; 35(3):205-12. PubMed ID: 7805178
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Redei I, Green F, Hoffman JP, Weiner LM, Scher R, O'Dwyer PJ.
    Invest New Drugs; 1994 Oct 15; 12(4):319-21. PubMed ID: 7775133
    [Abstract] [Full Text] [Related]

  • 7. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.
    J Clin Oncol; 1999 Oct 15; 17(10):3276-82. PubMed ID: 10506630
    [Abstract] [Full Text] [Related]

  • 8. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB.
    J Clin Oncol; 2001 May 01; 19(9):2413-21. PubMed ID: 11331320
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B, Luis R, Jaime M, Franceschi D.
    Cancer Invest; 1998 May 01; 16(4):237-51. PubMed ID: 9589033
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1992 May 01; 29(4):305-8. PubMed ID: 1537077
    [Abstract] [Full Text] [Related]

  • 19. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM.
    J Clin Oncol; 1999 May 01; 17(5):1580-8. PubMed ID: 10334547
    [Abstract] [Full Text] [Related]

  • 20. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ.
    Eur J Cancer; 1997 Oct 01; 33(11):1896-9. PubMed ID: 9470854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.